Abzena is a bioconjugate- and biologics-focused CDMO that pushes development of novel treatments forward at every stage from discovery through commercial launch. With the ability to tailor its strategy and customer experience to each project, Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their investments in human health. The company has research, development, and cGMP facilities across locations in San Diego, CA, Bristol, PA, and Cambridge, UK

Abzena is a bioconjugate- and biologics-focused CDMO that pushes development of novel treatments forward at every stage from discovery through commercial launch. With the ability to tailor its strategy and customer experience to each project, Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their investments in human health. The company has research, development, and cGMP facilities across locations in San Diego, CA, Bristol, PA, and Cambridge, UK

At Cellistic, we believe the real potential of cell therapy is allogeneic and iPSC-based – and it’s ready to be unlocked. We’ve founded our company to accelerate the development and manufacture of your cell therapies in a more reliable, affordable, and faster way, using our exclusive Pulse™ + Echo™ Platforms. This family of established manufacturing processes for cell line development and cell therapy manufacturing can take your innovation from idea to edited and banked iPSCs, and then from iPSCs to drug product – all while keeping it in the expert hands of a single, experienced development team.

Ncardia is a human iPSC technology company that operates worldwide with facilities, offices, and staff throughout Europe and North America. Ncardia is built on the belief that stem cell technology will help bring better therapies to patients faster. The company’s goal is to enable biopharmaceutical companies in drug discovery and cell therapy to accelerate their development processes through the integration of human iPSC technologies.

Locus Biosciences’ novel approach to precision antimicrobials works by taking advantage of a part of an immune system present in many bacteria called the CRISPR-Cas system. The CRISPR-Cas system protects bacteria from invaders such as viruses by creating small strands of RNA called CRISPR RNAs, which match DNA sequences specific to a given invader. When those CRISPR RNAs find a match, they activate Cas proteins that cut the DNA.

Mr. Glass is the founding principal of Clear Sciences, LLC a management consulting company focused on the Life Sciences industry.

Mr. Glass created and was responsible for Patheon's product business unit, known as Banner Life Sciences. His responsibilities included the research, development and commercialization of products on a worldwide basis across the landscape of nutritional, over-the-counter and prescription medicines and P&L management of all corresponding groups and regions.

Geoffrey M. Glass was the Executive Vice President of Global Strategy, Sales and Marketing at Patheon. Mr. Glass is a member of the Executive Management team and leads the company’s Sales, Marketing, Pricing, Strategy, Business Intelligence and Contracting groups world-wide.

Geoffrey M. Glass, Senior Vice President of Strategy, Corporate Development and Integration, joined Patheon’s Executive team. Mr. Glass led the company’s global Strategy, Partnership and Acquisition programs, and Marketing functions on a world-wide basis.

Geoffrey M. Glass was Senior Vice President of Asian Operations at Valeant Pharmaceuticals. He has responsibilities for all of Valeant's business affairs in the region.

Geoffrey M. Glass was Senior Vice President and Chief Information Officer of Valeant Pharmaceuticals International. In this role, Mr. Glass was responsible for all technology, project management, six sigma and business integration-related matters for the company.

Mr. Glass was the Global Leader of Life Sciences Operations Excellence Practice for Cap Gemini (formerly Ernst & Young LLP Consulting). During his tenure at Cap Gemini, Mr. Glass led global teams through the successful implementation of business transformations at a number of leading life sciences organizations, including Abbott Laboratories, Amgen, Biogen Idec, DuPont,